title: [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
abstract: The use of beta-interferons for immunomodulating treatment of multiple sclerosis (MS) in children is rstudied. We present results of the prospective study of 22 children, aged 13-17 years, with MS treated with beta-interferon-1b (betaferon) during 2-15 (mean 10,72) months. High efficacy and good tolerability of beta-interferon-1b is demonstrated.
authors.forename: O V
authors.initials: OV
authors.lastname: Bykova
authors.forename: L M
authors.initials: LM
authors.lastname: Kuzenkova
authors.forename: O I
authors.initials: OI
authors.lastname: Maslova
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D002648:Child; D003866:Depressive Disorder / Q000453:epidemiology / Q000523:psychology; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta